South & Central America Cell and Gene Therapy Market Forecast to 2031 - Regional Analysis - by Type, Services, Scale, Service Providers, and End User

The South & Central America cell and gene therapy market was valued at US$ 67.28 million in 2023 and is projected to reach US$ 184.80 million by 2030; it is estimated to record a CAGR of 13.5% from 2023 to 2031.

Strategic Initiatives by Companies Boost South & Central America Cell and Gene Therapy Market

Many companies involved in manufacturing cell and gene therapy products focus on collaborations, expansions, agreements, partnerships, new product launches, and other strategic developments. These strategic initiatives help them improve sales, expand geographic reach, and enhance capacities to cater to a large customer base. A few of the significant developments in the cell and gene therapy market are as In March 2022, Cellevolve Bio partnered with Seattle Children’s Therapeutics to develop and commercialize new multiplex CARs for pediatric cancers. With this collaboration, the companies will focus on the BrainChild research program - a suite of five multiplex CARs - to treat pediatric central nervous system (CNS) malignancies. They aim to leverage the Seattle Children’s Cure Factory facility to conduct early clinical GMP research on new CARs. In March 2022, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Also, the companies aim to combine Twist’s antibody libraries with Kriya’s proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya’s gene therapy technology. In January 2022, FUJIFILM Corporation agreed to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. The facility will witness expansion with the flexibility to produce clinical as well as commercial cell therapies, such as allogeneic T-cell and CAR T immunotherapies.

The initiation of new businesses to remain competitive in the market through collaborations and partnerships can help accelerate the development of new platforms for cell and gene therapy manufacturing services. Thus, these strategic initiatives by key players are anticipated to create substantial growth opportunities in the South & Central America cell and gene therapy market during the forecast period.

South & Central America Cell and Gene Therapy Market Overview

Both profit and nonprofit organizations are propelling advanced medical product access and development in Brazil. In March 2024, for example, the Brazilian government's Fundação Oswaldo Cruz (Fiocruz), a foundation under the Ministry of Health in Brazil, partnered with Caring Cross, a 501(c)(3) nonprofit organization committed to advancing the development of cutting-edge medical treatments and facilitating access to all patients worldwide. Under this partnership, the government aims to establish local production of chimeric antigen receptor (CAR)-T cell and stem cell gene therapies for patients suffering from oncology, infectious, and genetic diseases in Brazil. These therapies also include CAR-T cell therapies for leukemia, lymphoma, and HIV infection. Brazil is attempting a novel collaboration between the Ministry of Health of Brazil and Fiocruz, the public health and research foundation. Therefore, a rise in the initiatives undertaken by profit and nonprofit organizations propel the market growth in the coming years.

South & Central America Cell and Gene Therapy Market Segmentation

The South & Central America cell and gene therapy market is categorized into type, services, scale, end user, and country.

Based on type, the South & Central America cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held a larger market share in 2023. Furthermore, the cell therapy segment is sub segmented into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is divided into non-viral vectors and viral vectors.

In terms of services, the South & Central America cell and gene therapy market is categorized process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest market share in 2023.

By scale, the South & Central America cell and gene therapy market is bifurcated into pre-commercial/R&D manufacturing and commercial scale manufacturing. The pre-commercial/R&D manufacturing segment held a larger market share in 2023.

Based on end user, the South & Central America cell and gene therapy market is segmented into contract research, organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the South & Central America cell and gene therapy market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America cell and gene therapy market share in 2023.

Catalent Inc, Charles River Laboratories International In, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, and Thermo Fisher Scientific Inc. are some of the leading companies operating in the South & Central America cell and gene therapy market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America cell and gene therapy market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the South & Central America cell and gene therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America cell and gene therapy market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.